OCUL Latest Headlines

Ocular Therapeutix (OCUL) Gets a Buy from H.C. Wainwright

at www.tipranks.com (Thu, 30-Apr 6:42 AM)

Ocular Therapeutix (OCUL) Receives a Buy from William Blair

at www.tipranks.com (Wed, 29-Apr 9:40 AM)

Ocular Therapeutix Targets New Milestones With Packed May Conference Schedule and Clinical Updates

Market Chameleon (Mon, 27-Apr 9:39 AM)

Ocular Therapeutix’s SOL-1 Data Showcases Unmatched Durability for AXPAXLI in Wet AMD—23 to 22-Week Advantage Over Standard Treatment

Market Chameleon (Mon, 13-Apr 9:11 AM)

Ocular Therapeutix to Unveil New SOL-1 Phase 3 Data on AXPAXLI for Wet AMD at April Conferences

Market Chameleon (Wed, 1-Apr 7:55 AM)

Ocular Therapeutix to Reveal Detailed SOL-1 Phase 3 Data at Macula Society Meeting—Investor Webcast Follows Key Disclosure

Market Chameleon (Mon, 23-Feb 7:07 AM)

AXPAXLI’s Superiority in Wet AMD Unveiled: SOL-1 Trial Delivers Historic Clinical Milestone for OCUL

Market Chameleon (Tue, 17-Feb 7:06 AM)

Ocular Therapeutix Grants Equity Awards to New Hires: What the Latest Inducement Plan Reveals

Market Chameleon (Mon, 9-Feb 8:14 AM)

Ocular Therapeutix Focuses on Pivotal Data Milestones and Regulatory Path as Cash Position Strengthens

Market Chameleon (Thu, 5-Feb 11:12 AM)

Ocular Therapeutix Expects Key Wet AMD Phase 3 Data at Macula Society—Cash Runway and Multiple Trials Position Company for 2028

Market Chameleon (Thu, 5-Feb 8:11 AM)